drugset / Trial / NCT05130047
Aldafermin (NGM282) for Chronic Diarrhea Due to Bile Acid Malabsorption (BAM)
RandomizedParallel-groupDouble-blindTreatment
Summary
This single-center, randomized, double-blind, placebo-controlled study is designed to compare effects of aldafermin, (NGM282), 1 mg, and placebo given daily by subcutaneous injection on bowel functions and hepatic synthesis and fecal excretion of bile acids in patients with diarrhea associated with bile acid malabsorption (BAM).
Timeline
- Start
- 2021-12-01
- Primary completion
- 2022-11-08
- Completion
- 2022-11-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Aldafermin | Protein / enzyme biologic | 1 mg | Subcutaneous |